Folate vs Folic Acid: Why the Form You Take Actually Matters
If you've looked into folate recently — particularly during pregnancy planning or after a genetic test flagged the MTHFR variant — you'll have encountered a debate that splits opinion between GPs, nutritionists, and functional medicine practitioners.
The short version: folic acid and folate are not interchangeable. They're related compounds that behave differently in the body, and for a meaningful subset of the population, the distinction genuinely matters.
This article explains the difference, what the evidence supports, and what it means in practice when choosing a supplement.
What Is Folate?
Folate is the umbrella term for a group of water-soluble B vitamins (vitamin B9) that occur naturally in food. It's found predominantly in leafy greens, legumes, liver, and eggs. The biologically active form — the form your cells can actually use — is called 5-methyltetrahydrofolate, or 5-MTHF.
Folate plays a central role in:
- DNA synthesis and repair
- Cell division
- The methylation cycle — a key process in how your body regulates gene expression, detoxification, and neurotransmitter production
- Reducing levels of homocysteine, an amino acid associated with cardiovascular risk when elevated
- Neural tube development in early pregnancy
Natural dietary sources of folate — the form your body already knows how to use.
What Is Folic Acid?
Folic acid is the synthetic form of folate used in fortified foods and the majority of supplements on the market. It doesn't exist in nature. It was developed in the 1940s and became the standard supplementation form largely because of its stability — it doesn't degrade during manufacturing or storage the way natural folate does.
Folic acid is not biologically active. Before your body can use it, it must be converted through a series of enzymatic steps into 5-MTHF. The key enzyme in this process is called dihydrofolate reductase (DHFR).
This is where the problem begins.
The Conversion Problem
The DHFR enzyme has limited capacity. Research has shown that high doses of folic acid can exceed this capacity, leading to a build-up of unmetabolised folic acid (UMFA) in the bloodstream. Unlike active 5-MTHF, folic acid must undergo multiple DHFR-dependent reduction steps before it can enter the methylation pathway — a process that limits folate utilisation in individuals with impaired enzyme function.
The clinical significance of circulating UMFA is still being investigated, but it represents a real biochemical mechanism and a legitimate reason why assuming "more folic acid is always better" is not supported by the evidence.
For most people with normal DHFR function, this conversion process works adequately at standard supplementation doses. The picture changes for those carrying a common genetic variant.
The MTHFR Gene: What It Is and How Common It Is
MTHFR stands for methylenetetrahydrofolate reductase — the enzyme responsible for the final conversion step that produces active 5-MTHF from folate.
A genetic polymorphism in the MTHFR gene — specifically the C677T variant — reduces the efficiency of this enzyme. In individuals who carry two copies of this variant (homozygous TT), enzyme activity can be reduced by approximately 70%. In heterozygous carriers (one copy), activity is reduced by around 35%.
This is not rare. In European populations, roughly 10–15% of people are homozygous (TT) and around 40–50% carry at least one copy. A large proportion of the population may therefore have a reduced ability to convert folic acid into the usable form — without knowing it.
Where MTHFR variants create a bottleneck — and why active methylfolate bypasses it.
What Happens If You Have an MTHFR Variant and Take Folic Acid?
If MTHFR enzyme function is reduced, the conversion of folic acid to active 5-MTHF is impaired. The MTHFR C677T polymorphism impairs enzyme function and is associated with elevated homocysteine in TT individuals — a marker that the methylation cycle is not running efficiently and a risk factor for cardiovascular complications.
For MTHFR carriers, supplementing with active methylfolate (5-MTHF) bypasses the impaired conversion step entirely. Clinical studies have shown that 5-MTHF achieves comparable — and in some studies higher — increases in red blood cell folate and greater homocysteine reduction, particularly in women with MTHFR variants, compared to standard folic acid supplementation.
The evidence base here is genuine. This is not fringe or conspiratorial — it reflects a well-characterised biochemical mechanism that clinical researchers are actively investigating.
What Does This Mean in Pregnancy?
This is where the distinction becomes consequential. The guidance to supplement with folate before conception and through the first trimester is well-established — it significantly reduces the risk of neural tube defects including spina bifida. The current NHS recommendation is 400mcg of folic acid daily before conception and for the first 12 weeks of pregnancy.
However, for women with MTHFR variants — particularly the homozygous TT genotype — the ability to convert that folic acid into the active form is significantly reduced. Research confirms that 5-MTHF is the predominant and more stable circulating form of folate during pregnancy, both in maternal and cord blood, indicating meaningful physiological differences between the two forms.
This has led a growing number of practitioners to recommend active methylfolate over synthetic folic acid for women planning pregnancy, particularly those who have tested positive for MTHFR variants. Some European countries have already updated national recommendations to reflect this. The NHS has not yet done so — which is partly why so many women are researching this topic independently.
Methylfolate vs Folic Acid: A Direct Comparison
| Folic Acid | Active Folate (5-MTHF) | |
|---|---|---|
| Form | Synthetic | Bioidentical to the body's own active form |
| Conversion required | Yes — multiple enzymatic steps | No — directly usable |
| MTHFR impact | Significant — conversion impaired | Bypasses MTHFR entirely |
| Evidence base | Extensive — decades of research | Robust and growing |
| NHS recommended form | Yes | Not currently — but widely used clinically |
| Cost | Lower | Higher |
What About People Without an MTHFR Variant?
For individuals with normal MTHFR function and at standard doses, folic acid has a strong safety and efficacy record. The neural tube defect data is compelling, built on large populations over decades.
The case for active folate is strongest for:
- Known MTHFR carriers, particularly homozygous TT
- Women with a history of recurrent pregnancy complications
- Those with persistently elevated homocysteine despite adequate intake
- Anyone with documented difficulties in methylation pathways
For the general population, active folate is not contraindicated — it simply removes the conversion requirement. There is no evidence that 5-MTHF is inferior to folic acid for anyone. Whether the additional cost is justified is a personal decision, but from a biochemical standpoint, the active form is unambiguously the more direct route.
What to Look for in a Folate Supplement
If you decide to opt for active folate over folic acid, the label matters.
Look for:
- 5-methyltetrahydrofolate (5-MTHF) — the biologically active form. You may also see it listed as methylfolate, L-methylfolate, or the branded ingredients Quatrefolic® or Metafolin®
- Dose expressed in mcg DFE (dietary folate equivalents) to allow meaningful comparison across products
- An additive-free formulation — no unnecessary bulking agents, artificial fillers, or flow agents
- Clearly stated dose per capsule or tablet
Avoid:
- Products labelling folic acid as if it is the active form — it isn't
- Proprietary blends that obscure the actual folate dose
- Multi-B-vitamin products where the individual folate dose is unclear
The Bottom Line
Folic acid and folate are not the same, and the difference is not merely semantic. For people with MTHFR variants — a large and largely untested segment of the population — the body's ability to convert synthetic folic acid into the active form is meaningfully reduced. Active methylfolate (5-MTHF) bypasses this limitation entirely.
The evidence for choosing active folate is particularly strong for women planning pregnancy who carry MTHFR variants, for those with elevated homocysteine, and for anyone who has had suboptimal results with standard folic acid supplementation.
If you don't know your MTHFR status, private testing in the UK is available from approximately £30–50. If you're planning a pregnancy and want to ensure your folate supplementation is being effectively converted and used, active methylfolate is the more defensible choice.
Health Leads UK Folate is formulated with 5-MTHF (5-methyltetrahydrofolate), with no unnecessary additives. View our Folate supplement →